Is Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?

Yahoo FinanceMar 29 20:04 ET

Paradigm Biopharmaceuticals Ltd: Appendix 4D and Half Year Report

ASXFeb 27 16:12 ET · Announcements

Paradigm Biopharmaceuticals Secures Ethics Committee Approval for Phase Three Knee Osteoarthritis Clinical Trial

MT NewswiresFeb 23 21:02 ET

Paradigm Biopharmaceuticals Ltd. (PBIGF) Receives a Buy From Bell Potter

TipRanksFeb 2 19:06 ET · Ratings

Paradigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%

MT NewswiresJan 30 20:33 ET

Paradigm Biopharmaceuticals Ltd: Paradigm Receives $6.3m R&D Tax Refund

ASXJan 23 16:59 ET · Announcements